Half day - 9.00-1.00pm - via Zoom
Thursday 10 June 2021, 9:00 AM - 1:00 PM
HTAs are increasingly considering the views of the patient in their decision making regarding the reimbursement and access to therapies.
With this in mind there been an increasing acceptance of patient preference studies:
- To support relevant endpoints in clinical studies (both RCT and RWE)
- To provide evidence for regulatory and HTA bodies that unique product features really can / will make a difference for patients
- In benefit-risk assessments
- In clinical pathway and treatment guideline development
- For reimbursement decision support
- For product / service development programs
- In publications
- In patient education
With the likes of the FDA, EMA, CADTH, NICE and GBA showing an interest in the outcome of these studies there is specific guidance on how these need to be undertaken to provide the robust level of data required by these bodies.
One group looking at this area to provide guidance on best practice is PREFER. PREFER looks at how and when it is best to perform and include patient preferences in decision making. It has the aim of establishing recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies on how and when to include patient perspectives on benefits and risks of medicinal products.
This workshop will touch on the methodological considerations and requirements as well the latest guidance from groups working in this area along with the practical steps to ensure acceptance of the final outputs by key stakeholders.
It is suitable for pharma insight managers and agency researchers involved in providing patient preference style research.
This workshop will be run for us by Ipsos Healthcare. We are very grateful to the team for sharing their time and expertise for the benefit of BHBIA members.
Ipsos has expertise in market access combined with physicians and patient expert researchers to give the complete picture with respect to the landscape of healthcare stakeholders. As patients gain a greater stake both in terms of knowledge and financing they have a key role and payer are more concerned about meeting their needs outside simple efficacy.
Speaker names will be confirmed closer to the event date.
'Early bird' delegate fees for bookings made on or before 15th April 2021:
- Members: £189 + VAT
- Non-Members: £234 + VAT
(These prices include a 10% early booking discount).
Cancellation Policy for early bird bookings: full fee payable / no refunds given; however a substitute delegate can be accepted. (Our standard cancellation policy does not apply).
Delegate Fees for bookings made after 15th April 2021:
- Members: £210 + VAT
- Non-Members: £260 + VAT
Cancellation Policy: standard cancellation policy applies, as stated on booking form